Identification of MAP3K15 as a potential prognostic biomarker and correlation with immune infiltrates in osteosarcoma

Abstract

Background: Osteosarcoma (OS) is a type of primary malignant tumor, and increasing evidence shows the clinical benefits of immunotherapy in treating OS. However, the lack of comprehensive studies on the complex OS immune microenvironment hinders the application of immunotherapy. Thus, this study aimed to systematically explore the immune characteristics of OS and identify novel biomarkers for OS treatment.Methods: We systematically studied the immune score and proportions of infiltrating immune cells in OS in the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and Gene Expression Omnibus (GEO) databases using the ESTIMATE and CIBERSORT algorithms. Differential expression and functional analyses were used to identify dysregulated genes and explore their functions.Survival and Cox regression analyses were applied to establish an immune-related prognostic signature.Additionally, qPCR and immunohistochemistry were performed to validate the results.Results: A total of 103 differentially expressed immune genes (DEIGs) were found in the TARGET-OS and GSE39058 databases, and these DEIGs were mainly enriched in leukocyte proliferation, leukocyte differentiation, osteoclast differentiation, natural killer (NK) cell-mediated cytotoxicity, and the adaptive immune system. A predictive signature was constructed based on the survival analysis, with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.65. Moreover, we found that mitogenactivated protein kinase kinase kinase 15 (MAP3K15) can predict the prognosis of patients with OS and is closely related to CD4 + T cells and macrophages. The OS patients with high MAP3K15 expression had a significantly poorer prognosis.Conclusions: Our study found that MAP3K15, whose expression level is closely related to immune activity in tumors, is a critical immune-related biomarker, and our findings may provide a basis for OS immunotherapy.

Association of novel MUC16, MAP3K15 and ABCA1 mutation with giant congenital melanocytic nevus

“…Several studies have found that members of the MAPK family function in a protein kinase signaling cascade and that MAP3K proteins play a role in regulating apoptosis [ 22 ]. It was found that MAP3K15 may be involved in tumorigenesis and development [ 23 ]. Importantly, our study identified mutations of the MAP3K15 gene in the dPGCMN tissue of patient 2#, which may have impaired the normal apoptotic program of melanocytes leading to uncontrolled cell proliferation.…”